Business Context and Reporting Period
This Form 8-K is a current report filed by InMed Pharmaceuticals Inc. on November 30, 2020. The filing addresses a correction to the Summary Compensation Table previously disclosed in the Company's Registration Statement on Form S-1 (filed October 8, 2020, effective November 12, 2020). The report clarifies that certain compensation for Named Executive Officers (NEOs) for the fiscal year ended June 30, 2020, which was previously undetermined, consists of bonus awards rather than non-equity incentive plan compensation.
Key Financial Metrics
The filing does not provide general corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to executive compensation adjustments for the fiscal year ended June 30, 2020.
| Executive Officer | Position | 2020 Bonus Awarded (USD) | 2020 Total Compensation (USD) |
|---|---|---|---|
| Eric A. Adams | President and CEO | $67,505 | $669,908 |
| Bruce Colwill | Chief Financial Officer | $42,580 | $327,648 |
| Alexandra Mancini | Sr. Vice President, Clinical & Regulatory Affairs | $38,284 | $379,558 |
Note: Bonuses were originally calculated in Canadian dollars and converted to U.S. dollars using the Bank of Canada average daily rate for the year ended June 30, 2020 (U.S.$1.00 = C$1.3426).
Material Changes Versus Prior Period
The filing corrects a misclassification in the prior Registration Statement. The amounts previously listed as "non-equity incentive plan compensation" that could not be calculated at the time of filing are now correctly identified as "bonus awards." Consequently, the Total Compensation figures for the NEOs for the fiscal year 2020 have been updated to include these specific bonus amounts.
Guidance, Outlook, and Risks
This filing contains no guidance, outlook, management commentary on business operations, or discussion of risks and contingencies. The document is strictly a disclosure of omitted bonus compensation pursuant to Item 5.02(f) of Regulation 8-K.
Key Facts for Investor Verification
- The filing corrects the classification of undetermined compensation for the fiscal year ended June 30, 2020, from non-equity incentive plans to bonus awards.
- Three NEOs received specific bonus awards totaling approximately $148,369 USD combined for the 2020 fiscal year.
- The updated Summary Compensation Table supersedes the table in the Form S-1 Registration Statement effective November 12, 2020.
- Compensation figures reflect a currency conversion from Canadian to U.S. dollars based on the 2020 average daily exchange rate.